Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc.

Key Points

• Contravisory Investment Management increased its Moderna stake by 1,387.6% in the second quarter, purchasing 22,590 additional shares and ending the period with 24,218 shares valued at approximately $1.696 million.
• Other institutional investors also added or initiated positions, with hedge funds and institutions collectively owning 75.33% of Moderna.
• Moderna reported better-than-expected second-quarter results, but remains loss-making; analysts maintain a mixed outlook, with the stock carrying an average “Reduce” rating and a consensus price target of $42.13.

Contravisory Investment Management Inc. increased its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 1,387.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,218 shares of the company's stock after purchasing an additional 22,590 shares during the quarter. Contravisory Investment Management Inc.'s holdings in Moderna were worth $1,696,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System acquired a new stake in Moderna in the first quarter worth $899,000. Lingotto Investment Management LLP boosted its holdings in shares of Moderna by 33.7% during the fourth quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company's stock valued at $14,706,000 after acquiring an additional 125,598 shares during the period. Nicollet Investment Management Inc. bought a new position in shares of Moderna during the fourth quarter worth about $897,000. Capital World Investors bought a new position in shares of Moderna during the fourth quarter worth about $378,299,000. Finally, Sigma Planning Corp acquired a new stake in shares of Moderna in the 4th quarter worth about $907,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved mFLUSIVA, Moderna’s mRNA-based seasonal influenza vaccine, for adults ages 50 and older. It is the first mRNA flu vaccine approved in the United States and Moderna’s fourth FDA-approved product, supporting the company’s effort to diversify beyond COVID-19. The company expects limited retail availability in the coming weeks. US FDA approves first mRNA flu shot from Moderna
• Positive Sentiment: On its second-quarter earnings call, Moderna maintained its 2026 growth target while lowering cost guidance. The combination of preserved revenue expectations and lower spending could improve cash runway and reduce concerns about the company’s post-pandemic revenue decline. Management also highlighted upcoming milestones for flu, oncology and rare-disease programs. Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
• Positive Sentiment: Moderna began a Phase 1 Canadian trial of an investigational mRNA vaccine for Bundibugyo ebolavirus, a strain without an approved vaccine. Although early-stage, the program reinforces the breadth of Moderna’s infectious-disease platform and its partnerships with CEPI and Canadian public-health authorities. Moderna Starts Phase 1 Canada Trial For Bundibugyo Ebola mRNA Vaccine
• Neutral Sentiment: The flu approval is a meaningful commercial opportunity, but Moderna still needs CDC recommendations, distribution and physician adoption to translate the regulatory win into material revenue. The initial authorization is limited to adults 50 and older, with established flu vaccines already competing for the upcoming season. Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
• Negative Sentiment: Investors continue to face substantial execution risk: COVID-related revenue has fallen sharply from pandemic highs, Moderna remains loss-making, and future valuation depends heavily on successful Phase 3 oncology results and broader pipeline commercialization. Some brokerages maintain a “Reduce” view, limiting the immediate impact of the positive headlines.

Moderna Price Performance

NASDAQ MRNA opened at $59.17 on Monday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $85.60. The company has a market capitalization of $23.62 billion, a P/E ratio of -7.41 and a beta of 0.91. The company's 50 day simple moving average is $60.28 and its 200 day simple moving average is $53.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company's revenue was up 2.1% compared to the same quarter last year. During the same period last year, the company posted ($2.13) EPS. Equities research analysts expect that Moderna, Inc. will post -6.2 earnings per share for the current fiscal year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 9,263 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director directly owned 3,924 shares in the company, valued at approximately $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares of the company's stock, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 119,406 shares of company stock valued at $5,928,762. Company insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MRNA. Royal Bank Of Canada lifted their price target on Moderna from $38.00 to $45.00 and gave the company a "sector perform" rating in a report on Tuesday, July 7th. Wolfe Research restated an "underperform" rating and issued a $25.00 target price on shares of Moderna in a research report on Monday, July 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Moderna in a research report on Friday, June 12th. Citigroup lifted their target price on Moderna from $41.00 to $60.00 and gave the company a "neutral" rating in a research note on Monday, August 3rd. Finally, Piper Sandler reiterated an "overweight" rating on shares of Moderna in a research report on Monday, August 3rd. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and an average target price of $42.13.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source